Designer estrogens: breast cancer benefit, remaining questions.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002278:Carcinoma in Situ / Q000188:drug therapy; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010880:Piperidines / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D010880:Piperidines; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride